Elevance Health, Inc. $ELV Stock Acquired by Candriam S.C.A.

Key Points

• Candriam S.C.A. increased its Elevance Health stake by 49.9% in the third quarter, buying 30,409 shares and bringing its holding to 91,310 shares, valued at about $35.6 million.
• Elevance reported quarterly earnings of $6.99 per share, above the $4.71 analyst consensus, and revenue of $50.44 billion, also exceeding expectations.
• Analyst sentiment was generally positive: 15 analysts rated the stock a Buy and seven a Hold, for a “Moderate Buy” consensus and an average price target of $456.48.

Candriam S.C.A. boosted its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 49.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 91,310 shares of the company's stock after purchasing an additional 30,409 shares during the quarter. Candriam S.C.A.'s holdings in Elevance Health were worth $35,633,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Field & Main Bank lifted its holdings in shares of Elevance Health by 1.3% in the second quarter. Field & Main Bank now owns 1,883 shares of the company's stock worth $728,000 after buying an additional 25 shares in the last quarter. Simplicity Wealth LLC boosted its position in shares of Elevance Health by 1.3% in the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company's stock valued at $754,000 after acquiring an additional 25 shares during the period. Tranquilli Financial Advisor LLC grew its stake in Elevance Health by 1.3% during the second quarter. Tranquilli Financial Advisor LLC now owns 2,081 shares of the company's stock valued at $805,000 after acquiring an additional 26 shares in the last quarter. Mather Group LLC. grew its stake in Elevance Health by 3.5% during the third quarter. Mather Group LLC. now owns 766 shares of the company's stock valued at $298,000 after acquiring an additional 26 shares in the last quarter. Finally, 55 North Private Wealth LLC increased its holdings in Elevance Health by 4.5% during the 3rd quarter. 55 North Private Wealth LLC now owns 598 shares of the company's stock worth $233,000 after acquiring an additional 26 shares during the period. Hedge funds and other institutional investors own 89.24% of the company's stock.

Elevance Health Stock Performance

Shares of ELV opened at $426.17 on Monday. The company has a market cap of $92.08 billion, a PE ratio of 18.17, a price-to-earnings-growth ratio of 2.03 and a beta of 0.63. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock has a 50-day moving average price of $412.92 and a 200-day moving average price of $373.58. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $450.69.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping the consensus estimate of $4.71 by $2.28. The company had revenue of $50.44 billion for the quarter, compared to analysts' expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. Elevance Health's revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the prior year, the business earned $6.03 earnings per share. As a group, equities analysts forecast that Elevance Health, Inc. will post 29.15 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. Elevance Health's dividend payout ratio is presently 29.34%.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Insiders Place Their Bets

In other news, CFO Mark Kaye sold 10,584 shares of the firm's stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the sale, the chief financial officer owned 19,919 shares in the company, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Ratnakar Lavu sold 1,300 shares of the firm's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total transaction of $572,000.00. Following the sale, the executive vice president owned 14,849 shares in the company, valued at approximately $6,533,560. This trade represents a 8.05% decrease in their position. The SEC filing for this sale provides additional information. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ELV has been the topic of several recent analyst reports. UBS Group increased their target price on shares of Elevance Health from $460.00 to $523.00 and gave the stock a "buy" rating in a research note on Thursday, October 22nd. Mizuho set a $490.00 price target on shares of Elevance Health in a report on Friday, October 23rd. Morgan Stanley boosted their price target on shares of Elevance Health from $404.00 to $449.00 and gave the company an "equal weight" rating in a research report on Thursday, October 22nd. Leerink Partners upped their price target on shares of Elevance Health from $364.00 to $395.00 and gave the stock a "market perform" rating in a report on Friday, July 17th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Elevance Health in a report on Thursday, August 13th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $456.48.

About Elevance Health

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.